Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.54 |
| ▸ | HTR3A | P46098 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7552913 | 0.75 | CHRNA7 (0.63) | CHRNA7HTR3ANPC1SMN1; SMN2RAB9A | |
| SCHEMBL2135825 | 0.75 | POLB (0.55) | POLBNPC1TDP1HPGDSMN1; SMN2 | |
| SCHEMBL18930708 | 0.74 | POLB (0.58) | POLBNPC1TDP1HPGDSMN1; SMN2 | |
| SCHEMBL8696408 | 0.73 | HPGD (0.63) | POLBNPC1TDP1HPGDSMN1; SMN2 | |
| SCHEMBL3144462 | 0.73 | ACE (0.64) | POLBNPC1TDP1HPGDSMN1; SMN2 | |
| SCHEMBL5742165 | 0.73 | ACE (0.64) | POLBNPC1TDP1HPGDSMN1; SMN2 | |
| SCHEMBL27918438 | 0.73 | NPC1 (0.56) | POLBNPC1TDP1HPGDSMN1; SMN2 | |
| SCHEMBL5672214 | 0.73 | PREP (0.58) | CHRNA7HTR3ASMN1; SMN2RAB9AKMT2A | |
| SCHEMBL10509497 | 0.72 | NPC1 (0.55) | POLBNPC1TDP1HPGDSMN1; SMN2 | |
| SCHEMBL14645896 | 0.72 | ACE (0.59) | POLBNPC1TDP1F2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124678-A1 | TREATMENT WITH ALPHA 7-SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124678-A1 | TREATMENT WITH ALPHA 7-SELECTIVE LIGANDS | CHRNA7, CHRNA1, CHRNG | CHRNA7 1/4885HTR3A 152/4885POLB 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.